Sõda

MEEDIAVALVUR: algab „sõjalise erioperatsiooni“ teine etapp nimega „SÕDA“

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3][1]

References

Kommenteeri